KUALA LUMPUR: While a patient group and an oncologist welcome the big price drop of trastuzumab, a breast cancer drug for HER2-positive patients, they urge the Health Ministry to remove the limiting criteria for selecting HER2+ patients to be treated.
Instead, they said HER2-positive patients should be given the choice to be treated regardless of age and cancer stage.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
